Brensocatib improves clinical outcomes in bronchiectasis patients: NEJM
Delhi: The use of brensocatib was shown to improve clinical outcomes in bronchiectasis patients, in a 24-week trial. The findings of the study are published in the New England Journal of Medicine. Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), helped in reducing neutrophil serine protease activity.
Bronchiectasis patients experience frequent exacerbation that are thought to be linked to neutrophilic inflammation. In bronchiectasis patients, the quantity and activity of neutrophil serine proteases, including neutrophil elastase, are increased in the sputum, and are increased further during exacerbation.
James D. Chalmers, Ninewells Hospital and Medical School, Dundee (J.D.C.), and colleagues performed phase 2, randomized, double-blind, placebo-controlled trial. It included 256 patients with bronchiectasis who had had at least two exacerbations in the previous year. They were randomized to receive placebo (n=87), 10 mg of brensocatib (n=82), or 25 mg of brensocatib (n=87) once daily for 24 weeks in the ratio of 1:1:1.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.